Alx Oncology Holdings (ALXO) Income from Continuing Operations (2019 - 2026)
Alx Oncology Holdings (ALXO) reported Income from Continuing Operations of 21620000.0 for Q1 2026, up 29.68% on a YoY basis from 16672444.19 in Q1 2025, and up 6.3% sequentially from 23074000.0 in Q4 2025.
Alx Oncology Holdings (ALXO) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of Income from Continuing Operations data on file, last reported at 21620000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 29.68% year-over-year to 21620000.0; the trailing twelve-month figure through Mar 2026 stood at 95962000.0 (up 27.86% YoY), and the FY2025 full-year result was 497000.0, up 99.53% from the prior year.
- Income from Continuing Operations rose to 21620000.0 in Q1 2026, from 23074000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 21620000.0 in Q1 2026 to a low of 50989000.0 in Q3 2023.
- A 5-year average of 32892882.35 and a median of 30743000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 1555.03% in 2022 and soared 39.77% in 2024, its largest moves.
- Tracing ALXO's Income from Continuing Operations over 5 years: stood at 30643000.0 in 2022, then tumbled by 49.01% to 45662000.0 in 2023, then soared by 35.36% to 29516000.0 in 2024, then climbed by 21.83% to 23074000.0 in 2025, then increased by 6.3% to 21620000.0 in 2026.
- Business Quant data shows ALXO's Income from Continuing Operations at 21620000.0 in Q1 2026, 23074000.0 in Q4 2025, and 22138000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | -21.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.62 Mn |
| Dec 31, 2025 | -23.07 Mn |
| Sep 30, 2025 | -22.14 Mn |
| Jun 30, 2025 | -29.13 Mn |
| Mar 31, 2025 | -30.74 Mn |
| Dec 31, 2024 | -29.52 Mn |
| Sep 30, 2024 | -30.71 Mn |
| Jun 30, 2024 | -42.06 Mn |
| Mar 31, 2024 | -38.42 Mn |
| Dec 31, 2023 | -45.66 Mn |
| Sep 30, 2023 | -50.99 Mn |
| Jun 30, 2023 | -37.37 Mn |
| Mar 31, 2023 | -31.83 Mn |
| Dec 31, 2022 | -30.64 Mn |
| Sep 30, 2022 | -35.31 Mn |
| Jun 30, 2022 | -34.44 Mn |
| Mar 31, 2022 | -25.52 Mn |
| Dec 31, 2021 | 2.11 Mn |
| Sep 30, 2021 | -24.57 Mn |
| Jun 30, 2021 | -16.27 Mn |